Multimodal Care for Patients With Alopecia Areata
August 6th 2025Panelists discuss how managing alopecia areata (AA) involves multiple health care specialties, including dermatology and mental health, and how multidisciplinary care can be optimized, while also addressing strategies to alleviate financial barriers that patients may face in accessing treatment.
Advancing First-Line Therapy for Multiple Myeloma: Updates From IsKia and IMROZ Trials
August 5th 2025Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity rates by approximately 10% at both the 10–5 and 10–6 levels, particularly benefiting high-risk patients.
PERSEUS and ADVANCE Updates: Evolving Approaches to MRD-Driven Myeloma Care
August 5th 2025Panelists discuss how the PERSEUS trial’s subgroup analysis reinforced that sustained minimal residual disease negativity predicts better long-term outcomes and demonstrated the potential for treatment de-escalation at the 2-year mark, while other trials like Advance showed dramatic increases in MRD negativity rates with quadruplet therapy.
Building Hidradenitis Suppurativa Treatment Plan: Evaluating Standard of Care Pharmacotherapies
August 1st 2025Panelists discuss the importance of coordinated, personalized treatment strategies for hidradenitis suppurativa, highlighting early use of pharmacologic therapies—including biologics—and ongoing assessment to balance clinical effectiveness, patient quality of life, and financial considerations.
Exploring The Future of NF1-PN Management
August 1st 2025Panelists discuss the future of NF1-associated plexiform neurofibromas management, highlighting the potential for advances in targeted therapies, gene therapies, and personalized medicine to offer more effective, tailored treatments, while emphasizing early detection, improved imaging, and a greater focus on quality of life through psychosocial support, pain management, and functional rehabilitation.
Proactive Hidradenitis Suppurativa Management: From Watchful Waiting to Active Intervention
August 1st 2025Panelists discuss optimizing hidradenitis suppurativa management through early intervention, personalized treatment based on disease severity, and multidisciplinary coordination led by dermatologists to improve patient outcomes and reduce disease burden.
Psychosocial Impact of Alopecia Areata
July 30th 2025Panelists discuss how ongoing or recurrent hair loss in patients with alopecia areata (AA) leads to significant psychological effects, impacting their mental health, and how different forms of AA may be harder for some patients to cope with, with strategies for managing these psychological challenges in clinical practice.
Key Takeaways From CEPHEUS: Subgroup Analysis
July 29th 2025Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that even higher-risk and less-fit patients can benefit from 4-drug combinations while maintaining acceptable safety profiles.
Expert Perspectives on Balancing QOL, Convenience, and Depth of Treatment Response
July 29th 2025Panelists discuss how quality of life (QOL) and treatment convenience should be balanced with maximal depth of response through personalized therapy approaches, emphasizing the importance of multidisciplinary care teams and the flexibility to adapt treatment regimens based on individual patient preferences and circumstances.
Health Equity in Hidradenitis Suppurativa: Addressing Care Disparities
July 25th 2025Panelists discuss the significant disparities in hidradenitis suppurativa diagnosis and care, emphasizing the impact of race, gender, geography, and socioeconomic status, and highlighting the need for culturally competent education, expanded access, and community engagement to promote earlier intervention and equitable outcomes.
Potential of Gene Therapy for NF1-PN
July 25th 2025Panelists discuss the mechanisms of action of gene therapy for NF1-associated plexiform neurofibromas, focusing on restoring functional neurofibromin to regulate the RAS/MAPK pathway and prevent tumor formation, while highlighting promising early clinical trial results showing reduced tumor volume and improved symptoms, alongside the need for further studies to assess long-term safety and efficacy.
The Pharmacist Advantage: Bridging Gaps in Hidradenitis Suppurativa Care
July 25th 2025Panelists discuss the vital role of multidisciplinary collaboration, provider education, and technology integration in improving early diagnosis and comprehensive management of hidradenitis suppurativa, highlighting how coordinated efforts across specialties—including pharmacists—can reduce delays, enhance equity, and optimize patient outcomes.
Therapy Selection and Management Strategies for Transplant-Ineligible Older Patients
July 22nd 2025Panelists discuss how newer immune-based therapies and bispecific antibodies may enable fixed-duration treatment approaches that could eliminate the need for stem cell transplant in older but fit patients, potentially allowing for treatment-free intervals after achieving deep responses.
Balancing Deeper Response and MRD Negativity With Toxicity Risks in Clinical Decision-Making
July 22nd 2025Panelists discuss how to balance achieving deeper MRD-negative responses against increased toxicity risks in transplant-ineligible patients by personalizing therapy through dose modifications, weekly vs twice-weekly dosing schedules, and careful monitoring while maintaining treatment intensity similar to clinical trials.
Common Comorbidities Associated With Alopecia Areata
July 21st 2025Panelists discuss how concurrent comorbidities, such as thyroid disorders and other autoimmune conditions, are commonly seen in patients with alopecia areata (AA) and how they complicate disease management and increase the overall burden on patients.
Hidden in Plain Sight: Strategies to Improve Early Identification of Hidradenitis Suppurativa
July 18th 2025Panelists discuss the drivers and consequences of delayed diagnosis in hidradenitis suppurativa, emphasizing the need for provider education, clinical decision support, and multidisciplinary collaboration to promote earlier recognition and more effective, coordinated care.
Recognizing Hidradenitis Suppurativa: From First Signs to an Accurate Diagnosis
July 18th 2025Panelists discuss the challenges of timely diagnosis and comprehensive management of hidradenitis suppurativa, emphasizing the need for early recognition, multidisciplinary care, and empathy-centered approaches to address the physical, emotional, and social burden of the disease.
Guideline Recommendations for Newer NF1-PN Therapies
July 18th 2025Panelists discuss current guidelines recommending mirdametinib for pediatric patients (2 years and older) with progressive, symptomatic NF1-associated plexiform neurofibromas that are inoperable or difficult to manage surgically, and emphasize the importance of early initiation, regular monitoring, and a multidisciplinary approach to optimize treatment outcomes.
Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics
July 15th 2025Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for personalized treatment strategies that consider individual patient frailty and high-risk genetics rather than applying uniform approaches across all older patients.
The Role of Biomarkers in NF1-PN Care
July 11th 2025Panelists discuss how biomarkers, including genetic testing and tumor profiling, can help identify patients with RAS/MEK/ERK pathway activation or specific NF1 mutations, enabling more personalized and effective treatment with therapies like mirdametinib or gene therapies for progressive, symptomatic NF1-associated plexiform neurofibromas.
Final Panelist Thoughts on the Management of Pulmonary Arterial Hypertension
July 10th 2025Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients with other forms of pulmonary hypertension and those with significant comorbidities.
Outlining the Need for Equitable Access to Care
July 10th 2025Panelists discuss how cost-effectiveness analyses of newer therapies like sotatercept show substantial benefits in reducing clinical worsening events and potentially decreasing downstream costs through reduced hospitalizations and transplantations, supporting value-based payment models.
Future Directions: Addressing Persistent Challenges in Fibrosis Care
July 9th 2025Panelists discuss that improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires multifaceted efforts including developing patient-centered clinical measures, managing comorbidities, leveraging digital health tools for real-time monitoring, and addressing health equity to ensure timely, personalized care that truly reflects patients’ lived experiences.
Beyond the Data: Evidence-Based Decision-Making in IPF and PPF Management
July 9th 2025Panelists discuss the shift toward patient-centered outcomes in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis treatment, emphasizing quality of life and symptom relief alongside lung function, while expressing optimism that emerging therapies may eventually reverse or prevent fibrosis, fundamentally transforming disease management.
Managing Early Relapse in Transplant-Eligible MM and the Influence of Clonal Evolution
July 8th 2025Panelists discuss how early relapse in standard-risk patients represents a failure of current risk assessment methods and may require advanced sequencing technologies to identify hidden high-risk features that traditional fluorescence in situ hybridization testing misses.